株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

転移性乳癌:パイプライン分析

Metastatic Breast Cancer - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 229722
出版日 ページ情報 英文 1079 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
転移性乳癌:パイプライン分析 Metastatic Breast Cancer - Pipeline Review, H1 2016
出版日: 2016年05月31日 ページ情報: 英文 1079 Pages
概要

転移性乳癌(ステージIV期または進行性)とは、癌細胞が乳房の腫瘍から転移して体の他の部位に広がり、増え続けている状態を指します。転移性乳癌の症状は、激痛、進行性の痛み、まれに病的な骨折、患部の骨の紅斑、腫れ、黄疸、肝酵素の上昇、腹痛、食欲不振、悪心、嘔吐などが見られます。治療には、ホルモン療法、化学療法、放射線療法、外科手術などが含まれます。

当レポートでは、転移性乳癌に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

転移性乳癌の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 未確認段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • AB Science SA
  • AbbVie Inc.
  • Acceleron Pharma, Inc.
  • Acetylon Pharmaceuticals, Inc.
  • Adgero Biopharmaceuticals, Inc.
  • Advaxis, Inc.
  • Advenchen Laboratories, LLC
  • Alteogen Inc.
  • Amarna Therapeutics B.V.
  • Ambrx, Inc.
  • Amgen Inc.
  • Aphios Corporation
  • arGEN-X BV
  • Aslan Pharmaceuticals Pte. Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Beta Pharma, Inc.
  • Biocon Limited
  • Bionovis SA
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Campus Technologies Freiburg GmbH 他

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7968IDB

Summary

Global Markets Direct's, 'Metastatic Breast Cancer - Pipeline Review, H1 2016', provides an overview of the Metastatic Breast Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Breast Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Breast Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer
  • The report reviews pipeline therapeutics for Metastatic Breast Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Metastatic Breast Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Metastatic Breast Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Metastatic Breast Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Breast Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metastatic Breast Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Metastatic Breast Cancer Overview
  • Therapeutics Development
  • Metastatic Breast Cancer - Therapeutics under Development by Companies
  • Metastatic Breast Cancer - Therapeutics under Investigation by Universities/Institutes
  • Metastatic Breast Cancer - Pipeline Products Glance
  • Metastatic Breast Cancer - Products under Development by Companies
  • Metastatic Breast Cancer - Products under Investigation by Universities/Institutes
  • Metastatic Breast Cancer - Companies Involved in Therapeutics Development
  • Metastatic Breast Cancer - Therapeutics Assessment
  • Drug Profiles
  • Metastatic Breast Cancer - Recent Pipeline Updates
  • Metastatic Breast Cancer - Dormant Projects
  • Metastatic Breast Cancer - Discontinued Products
  • Metastatic Breast Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Metastatic Breast Cancer, H1 2016
  • Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Development by Companies, H1 2016 (Contd..14)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Metastatic Breast Cancer - Pipeline by AB Science SA, H1 2016
  • Metastatic Breast Cancer - Pipeline by AbbVie Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Acceleron Pharma, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Adgero Biopharmaceuticals, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Advaxis, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016
  • Metastatic Breast Cancer - Pipeline by Alteogen Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Amarna Therapeutics B.V., H1 2016
  • Metastatic Breast Cancer - Pipeline by Ambrx, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Amgen Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Aphios Corporation, H1 2016
  • Metastatic Breast Cancer - Pipeline by arGEN-X BV, H1 2016
  • Metastatic Breast Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2016
  • Metastatic Breast Cancer - Pipeline by Astellas Pharma Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by AstraZeneca Plc, H1 2016
  • Metastatic Breast Cancer - Pipeline by Bayer AG, H1 2016
  • Metastatic Breast Cancer - Pipeline by Beta Pharma, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Biocon Limited, H1 2016
  • Metastatic Breast Cancer - Pipeline by Bionovis SA, H1 2016
  • Metastatic Breast Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Metastatic Breast Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Metastatic Breast Cancer - Pipeline by Campus Technologies Freiburg GmbH, H1 2016
  • Metastatic Breast Cancer - Pipeline by CASI Pharmaceuticals Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Celgene Corporation, H1 2016
  • Metastatic Breast Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Cellectar Biosciences, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Celltrion, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Clovis Oncology, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Corcept Therapeutics Incorporated, H1 2016
  • Metastatic Breast Cancer - Pipeline by Curadis GmbH, H1 2016
  • Metastatic Breast Cancer - Pipeline by Curaxys, S.L., H1 2016
  • Metastatic Breast Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Metastatic Breast Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016
  • Metastatic Breast Cancer - Pipeline by DexTech Medical AB, H1 2016
  • Metastatic Breast Cancer - Pipeline by Dompe Farmaceutici S.p.A., H1 2016
  • Metastatic Breast Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016
  • Metastatic Breast Cancer - Pipeline by EirGenix Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Eisai Co., Ltd., H1 2016
  • Metastatic Breast Cancer - Pipeline by Eli Lilly and Company, H1 2016
  • Metastatic Breast Cancer - Pipeline by Ensol Biosciences Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by EOS Biosciences, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Epigen Biosciences, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Etubics Corporation, H1 2016
  • Metastatic Breast Cancer - Pipeline by Eureka Therapeutics, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Metastatic Breast Cancer - Pipeline by Gene Techno Science Co., Ltd., H1 2016
  • Metastatic Breast Cancer - Pipeline by Genelux Corporation, H1 2016
  • Metastatic Breast Cancer - Pipeline by Genentech, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Genor BioPharma Co., Ltd., H1 2016
  • Metastatic Breast Cancer - Pipeline by Gilead Sciences, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Glycotope GmbH, H1 2016
  • Metastatic Breast Cancer - Pipeline by GTx, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
  • Metastatic Breast Cancer - Pipeline by Hetero Drugs Limited, H1 2016
  • Metastatic Breast Cancer - Pipeline by Immune Design Corp., H1 2016
  • Metastatic Breast Cancer - Pipeline by Immunomedics, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Immupharma Plc, H1 2016
  • Metastatic Breast Cancer - Pipeline by Imugene Limited, H1 2016
  • Metastatic Breast Cancer - Pipeline by Incyte Corporation, H1 2016
  • Metastatic Breast Cancer - Pipeline by Intas Pharmaceuticals Ltd., H1 2016
  • Metastatic Breast Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016
  • Metastatic Breast Cancer - Pipeline by Johnson & Johnson, H1 2016
  • Metastatic Breast Cancer - Pipeline by Kadmon Corporation, LLC, H1 2016
  • Metastatic Breast Cancer - Pipeline by Kancera AB, H1 2016
  • Metastatic Breast Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Laboratoires Pierre Fabre SA, H1 2016
  • Metastatic Breast Cancer - Pipeline by Mabion SA, H1 2016
  • Metastatic Breast Cancer - Pipeline by MacroGenics, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by MandalMed, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Meabco A/S, H1 2016
  • Metastatic Breast Cancer - Pipeline by MedImmune, LLC, H1 2016
  • Metastatic Breast Cancer - Pipeline by Medivation, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Merck & Co., Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Merck KGaA, H1 2016
  • Metastatic Breast Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Merus B.V., H1 2016
  • Metastatic Breast Cancer - Pipeline by MetaStat, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Morphotek, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Mycenax Biotech Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by NanoCarrier Co., Ltd., H1 2016
  • Metastatic Breast Cancer - Pipeline by NantKwest, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Natco Pharma Limited, H1 2016
  • Metastatic Breast Cancer - Pipeline by Nektar Therapeutics, H1 2016
  • Metastatic Breast Cancer - Pipeline by NewLink Genetics Corporation, H1 2016
  • Metastatic Breast Cancer - Pipeline by Nippon Kayaku Co., Ltd., H1 2016
  • Metastatic Breast Cancer - Pipeline by Northwest Biotherapeutics, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Novartis AG, H1 2016
  • Metastatic Breast Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2016
  • Metastatic Breast Cancer - Pipeline by OBI Pharma, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Oncobiologics, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Oncolytics Biotech Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Oncothyreon Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Metastatic Breast Cancer - Pipeline by Panacea Pharmaceuticals, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2016
  • Metastatic Breast Cancer - Pipeline by Pfizer Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Pharma Mar, S.A., H1 2016
  • Metastatic Breast Cancer - Pipeline by PIQUR Therapeutics AG, H1 2016
  • Metastatic Breast Cancer - Pipeline by Plexxikon Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Polyphor Ltd., H1 2016
  • Metastatic Breast Cancer - Pipeline by Prescient Therapeutics Limited, H1 2016
  • Metastatic Breast Cancer - Pipeline by Prima BioMed Ltd., H1 2016
  • Metastatic Breast Cancer - Pipeline by Puma Biotechnology, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Radius Health, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Samyang Holdings Corporation, H1 2016
  • Metastatic Breast Cancer - Pipeline by Sanofi, H1 2016
  • Metastatic Breast Cancer - Pipeline by Seattle Genetics, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016
  • Metastatic Breast Cancer - Pipeline by Starpharma Holdings Limited, H1 2016
  • Metastatic Breast Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016
  • Metastatic Breast Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016
  • Metastatic Breast Cancer - Pipeline by Synthon Holdings BV, H1 2016
  • Metastatic Breast Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016
  • Metastatic Breast Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Transgene Biotek Limited, H1 2016
  • Metastatic Breast Cancer - Pipeline by Vaxil Bio Therapeutics Ltd., H1 2016
  • Metastatic Breast Cancer - Pipeline by Verastem, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016
  • Metastatic Breast Cancer - Pipeline by VioQuest Pharmaceuticals, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Wilex AG, H1 2016
  • Metastatic Breast Cancer - Pipeline by WntResearch AB, H1 2016
  • Metastatic Breast Cancer - Pipeline by ZIOPHARM Oncology, Inc., H1 2016
  • Metastatic Breast Cancer - Pipeline by Zymeworks Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Metastatic Breast Cancer Therapeutics - Recent Pipeline Updates, H1 2016
  • Metastatic Breast Cancer - Dormant Projects, H1 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..1), H1 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..2), H1 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..3), H1 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..4), H1 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..5), H1 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..6), H1 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..7), H1 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..8), H1 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..9), H1 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..10), H1 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..11), H1 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..12), H1 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..13), H1 2016
  • Metastatic Breast Cancer - Discontinued Products, H1 2016
  • Metastatic Breast Cancer - Discontinued Products (Contd..1), H1 2016
  • Metastatic Breast Cancer - Discontinued Products (Contd..2), H1 2016
  • Metastatic Breast Cancer - Discontinued Products (Contd..3), H1 2016
  • Metastatic Breast Cancer - Discontinued Products (Contd..4), H1 2016

List of Figures

  • Number of Products under Development for Metastatic Breast Cancer, H1 2016
  • Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top